Skip to main
AZTA

Azenta (AZTA) Stock Forecast & Price Target

Azenta (AZTA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Azenta is a promising company with a strong future ahead, thanks to its innovative solutions in biological and chemical sample exploration and management. Its two segments, Sample Management Solutions and Multiomics, are both poised for impressive revenue growth in the coming years, leading to stronger margins and profitability. Despite potential headwinds such as increased competition in Multiomics, Azenta's strong market presence in the US and its plans for M&A activities could offset any potential negative impacts. Overall, investors can expect a solid return on investment in this stock.

Bears say

Azenta is expecting organic revenue growth and adjusted EBITDA margin expansion in FY26, driven by improvements in gross margin and opex leverage. Despite challenges in its end-markets, management believes that the company's initiatives in FY25 will support growth and margins. A potential sale of its B Medical business and the upcoming investor day could serve as positive catalysts. However, with the stock currently trading at a premium price, we remain cautious and have a negative outlook on Azenta's stock.

Azenta (AZTA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Azenta and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Azenta (AZTA) Forecast

Analysts have given Azenta (AZTA) a Buy based on their latest research and market trends.

According to 5 analysts, Azenta (AZTA) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Azenta (AZTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.